Celine Pitou

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

L. Buéno, Dinesh P. de Alwis, Celine Pitou et al. · European Journal of Cancer · 2007 · 202 citations

Molecular Pharmacology, Semi-mechanistic Modelling, New Type +10

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 137 citations

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

Johanna C. Bendell, Valérie André, Alan L. Ho et al. · Clinical Cancer Research · 2018 · 67 citations · Full text

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Liandong Ma, Joshua R. Clayton, Richard A. Walgren et al. · Blood Cancer Journal · 2013 · 64 citations · Full text

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Ignace Vergote, Florian Heitz, Paul Buderath et al. · Gynecologic Oncology · 2019 · 58 citations

Medicine, Pharmacology, Gynecology +7